Citi Downgrades Prime Medicine (PRME) to Neutral, 'Financing Risk Muddles the Path to Value Inflection'
Tweet Send to a Friend
Citi analyst Samantha Semenkow downgraded Prime Medicine (NASDAQ: PRME) from Buy to Neutral with a price target of $1.50 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
